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Abstract
Introduction: Little is known about the relationships 
between the T lymphocytes (CD3+) expression of 
glucocorticoid receptors (GCR) and the response to 
glucocorticoid treatment in children with idiopathic 
nephrotic syndrome (NS). The aim of the current study is 
to determine whether steroid responsiveness is dependent 
on the amount of T lymphocytes GCR expression
Methods: We studied 60 children with idiopathic NS in 
the age group from 2-10 years. According to the response 
to steroids we classified our patients into early responders 
(ER; n=46) and late responders (LR; n=14). Sixty age and 
gender matched healthy children represented the control 
group. The clinical and laboratory findings at baseline 
and GCR expression by T lymphocytes (CD3+) as 
determined by flow cytometry were compared between 
the three groups.
Results: The T lymphocytes (CD3+) expression of 
GCR was significantly lower in the LR than that in the 
control group (P<0.01), whereas it was similar in the ER 
and control groups. GCR expression was also decreased 
in the LR group compared to the ER group (P<0.01). 
Furthermore, the T lymphocytes (CD3+) expression 
of GCR correlated inversely with the time to complete 
remission (CR) (r = -0.54, P<0.05), but not with urinary 
protein excretion at baseline.
Conclusion: The levels of T lymphocytes (CD3+) 
expression of GCR may be a useful predictor of steroid 
responsiveness in children presenting with idiopathic 
NS.
Keywords: Flow Cytometry; Glucocorticoid Receptor; 
Idiopathic Nephrotic Syndrome; Steroid Responsiveness.
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Introduction
It is known that glucocorticoids (GC) therapy is the 
treatment of choice for young patients with idiopathic 
nephrotic syndrome (NS); however some patients fail to 
respond to the treatment even when given high-dose GC. 
For those patients, the treatment should be bolstered by 
synergizing GC with other immunosuppressant [1].
Although biochemical alterations and clinical 
manifestations in most nephrotic patients seem to be 
quite similar, substantial differences are encountered 
regarding the course of disease. Relapse of proteinuria 
is experienced in approximately 60% to 80% of steroid-
sensitive NS patients, and despite initial complete 
remission some remain steroid-dependent or become 
steroid-resistant [2].
The lack of response to corticosteroids has been 
explained by several mechanisms. It  may be ascribed 
to overwhelming disease severity, poor compliance, 
abnormalities in glucocorticoid metabolism or poor 
absorption, especially in patients with the NS, who 
often  develop heavy proteinuria and hypoalbuminemia, 
and, finally, by GC resistance due to a glucocorticoid 
receptor (GCR) or post-receptor abnormality. GCR was 
incriminated in worsening the response to steroids earlier 
[3,4], but inadequate response to steroids, either due to 
inherited target tissue defective response or acquired 
impaired responsiveness was  reported in a number of 
patients [5].
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(FCM) using monoclonal antibody  and FITC-Dex probes 
as described by Berki et al [7].
All Patients were treated according to the best clinical 
practice and evidence based guidelines [8]. They received 
oral prednisolone in single doses of 2.0 mg/kg/day 
followed by gradual tapering of the dosage if complete 
remission was achieved. The time interval from the start 
of glucocorticoid treatment to complete remission was 
calculated. Complete remission was defined as negative 
or trace proteinuria on urine dipstick tests and urinary 
protein to creatinine ratio <0.3 without oedema. Informed 
consent was obtained from parents and the protocol of the 
study was approved by the MMCH ethics committee.
Statistical analysis was performed using the statistical 
package SPSS for Windows Ver. 13.0 (SPSS, Inc., 
Chicago, IL, USA). Continuous variables were 
summarized as the mean ± SEM. Results were analyzed 
using the chi-square test or Mann-Whitney U non-
parametric test for multiple comparisons. Correlation 
between the expression of intracellular glucocorticoid 
receptors shown as the percentage of lymphocytes 
containing the receptors (CD3/GCR) and the time from 
the start of steroid treatment to complete remission was 
determined by Spearman correlation analysis. Statistical 
significance was determined when P values were less 
than 0.05.
Results
A total of 60 children with typical features of minimal 
change NS were recruited. Based on the response to 
glucocorticoid treatment, the patients were divided into 
two groups: 46 early responders (ER: 76.7%) and 14 
late responders (LR: 23.3%). There were no differences 
between the two groups regarding age, gender, or 
baseline laboratory parameters. The time from the start 
of steroid therapy to achievement of complete remission 
was significantly longer in the LR group (34  ± 4.1 
days)  than in the ER group (13± 3.2 days ), P<0.05. 
Demographic characteristics and laboratory findings of 
the study population are shown (Table-1).
The shortest time interval between the onset of steroid 
treatment and complete remission was 5 days while the 
longest time interval was 42 days.
The mean percentage of lymphocyte expression of 
glucocorticoid receptor (CD3+/GCR) was significantly 
lower in the LR group than that in the control group 
(42.8 ± 1.5 versus 89.1 ± 2.3; P < 0.01), whereas it was 
similar in the ER (88.2 ± 3.1) and control groups. GCR 
expression was also decreased in the LR compared with 
the ER group (P < 0.01) (Figure-1). The CD3/GCR% was 
significantly higher in the patients who achieved complete 
remission within the first week of steroid treatment 
(88.2 ± 0.3) compared to patients who did not achieve 
complete remission till the 6th week after initiation of 
steroid therapy (31.0 ± 2.3; P < 0.01) (Figure-2).
The expression of intracellular GCR shown as the 
percentage of lymphocytes containing the receptors was 
negatively correlated to the time interval from the start 
of steroid treatment to complete remission (r = -0.54 and 
P < 0.01) (Figure-3) 
The expression of intracellular GCR shown as the 
percentage of lymphocytes containing the receptors was 
not correlated to the urinary albumin/creatinine ratio 
(r = -0.01 and P > 0.01) (Figure-4).
Figure 1: Percentage of intracellular glucocorticoid receptor 
expression by lymphocytes (CD3/GCR) in controls, early 
responders and late responders
 
*  P < 0.01 when compared to control group and early responders.
Figure 2: The mean percentage of expression of intracellular 
glucocorticoid receptors by lymphocytes (CD3/GCR) in 
nephrotic syndrome patients according to the number of 
weeks required to achieve complete remission.
Prediction of clinical response before starting steroid 
therapy may lead to administration of synergized therapy 
at the beginning of the treatment and this will help avoid 
the side effects of chronic high-dose hormone therapy, 
improve the individual response to GC therapy and 
benefit more patients [6].
To our knowledge, there have been no published studies 
of the relationship between the expression of lymphocytes 
GCR and the time required to achieve complete remission 
in pediatric patients with steroid sensitive NS. 
We hypothesized that evaluation of GCR expression in 
children by a suitable method before treatment might 
be beneficial in predicting response to steroids. To 
investigate whether steroid responsiveness is dependent 
on the amount of T lymphocytes (CD3+) expression 
of GCR, we compared the expression of GCR by 
lymphocytes obtained from idiopathic NS patients 
who were categorized according to their response 
to glucocorticoids. Furthermore, we analyzed the 
correlations between the time interval from the start of 
GC therapy to complete remission and the amount of T 
lymphocytes (CD3+) expression of GCR.
Methods
This case control study was conducted in the nephrology 
and dialysis unit in Madinah Maternity and Children 
Hospital (MMCH), Saudi Arabia, between February 2009 
and January 2011. During this period 60 children in the 
age group 2-10 years with new-onset nephrotic syndrome 
(NS) were prospectively studied. NS was characterized 
by the presence of edema, proteinuria of at least 2.0 g/24 
hours (or urine protein/creatinine ratio of at least 2.0) and 
hypoalbuminemia (serum albumin <2.0 g/dl). Steroid 
responsiveness was defined as patients who went into 
complete remission within 2 months of oral prednisolone. 
Based on the response to glucocorticoid treatment, the 
patients were divided into two groups: early responders 
(ER) in whom complete remission was achieved within 
four weeks of steroid treatment and late responders (LR) 
in whom complete remission was achieved after four 
weeks of steroid treatment. Sixty, age and sex matched, 
children admitted for elective surgeries were recruited as 
a control group.  
We excluded patients with atypical NS as indicated 
by hypertension, elevated creatinine, or macroscopic 
hematuria. We also excluded patients with abnormal 
urinary sediments (abnormal casts or crystaluria) and 
patients with history of steroid intake for any cause 
during the previous 6 months.
All groups were assessed for basic demographic data and 
laboratory parameters (urinalysis, hemoglobin, blood 
urea nitrogen, serum creatinine, serum albumin, serum 
cholesterol, 24 hour urinary protein excretion, urinary 
protein to creatinine ratio, selective proteinuria index). The 
expression of intracellular glucocorticoid receptors was 
measured as the percentage of lymphocytes containing 
the receptors (CD3/GCR) and was determined in Taibah 
University Research Laboratory by flow cytometry 
Table 1:  Demographic and baseline laboratory parameters of the study groups
Control (n = 60) ER (n = 46, 76.7%) LR (n = 14, 33.3%)
Time to complete remission (days) 13 ± 3.2 34 ± 4.1*
Age 5 ± 2.3 5 ± 2.9 4 ± 3.8
Male/Female 38/22 32/14 8/6
Haemoglobin (g/dl) 13.8 ±1.8 14.5 ± 0.9 13.4 ± 0.2
BUN (g/dl) 13.7 ± 1.1 13.5  ± 1.6 12..9 ± 1.9
Creatinine (mg/dl) 0.4 ± 0.3 0.5 ± 0.4 0.4 ± 0.6
Total cholesterol (mg/dl) 165.4 ± 31.9 387.7 ± 22.3† 358.4 ± 41.5†
Serum albumin (g/dl) 4.3 ± 0.5 1.8 ± 0.9† 2.1 ± 0.7†
Urinary albumin/creatinine - 7 ± 1.5 8.9 ± 2.3
24 h urinary protein excretion (g/24 h) - 10 ± 0.5 8.9 ± 2.3
Selective protein index(SPI) - 0.12 ± 0.01 0.13 ± 0.07
Values are expressed as mean ± SEM; ER: early responders, complete remission achieved within 4 weeks of steroid therapy; LR: late responders, 
complete remission achieved after 4 weeks of steroid therapy.
* P < 0.05 compared to ER 
† P < 0.01 compared to controls
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Discussion
One of the most important indicators for the outcome 
of children with idiopathic NS is their initial response 
to GC treatment. Eventual cure is mostly a consequence 
of a good initial response of proteinuria to GC, even in 
the case of frequent relapses. Meanwhile, progression to 
renal failure may be the final destination for children who 
show an incomplete or absent response initially [9].
No conclusive explanation has been provided regarding 
the discrepancy in NS patients’ response to GC. 
Variations in the clearance rates of GC between patients 
are expected, and variations in the density of specific GC 
receptors may also exist [1-3]. Mononuclear leukocytes 
(MNL) expression of GC receptors was found to reflect 
the in-vivo effects of GC in healthy men as well as in 
patients with various autoimmune diseases such as 
rheumatoid arthritis, lupus nephritis and asthma [10]. 
Age, renal function at onset and selectivity of proteinuria 
were found to be associated with the response to steroid 
therapy in adults [4].
A pervious study explored the factors affecting the 
pattern of response to steroid therapy by dividing 
patients according to their response to steroids into early 
and late responders with a cut-off period of four weeks 
[11]. That study compared the frequency of relapses, but 
did not evaluate the differences in clinical or laboratory 
findings between the two groups. It reported that the 
age of onset in minimal change disease NS was not 
significantly correlated with steroid-responsive rate or 
with the time interval to remission [11]. The number or 
density of cellular GC receptors was found to determine 
cell response and the efficacy of GC on tumour cells in 
lymphoid leukaemia and lymphoma [12]. 
The results of the current study are in accordance with 
a previously cited study which showed that glomerular 
glucocorticoid receptor expression was reduced in late 
responders to steroids in adult-onset minimal change 
disease [10]. Moreover, current results showed a 
significant inverse correlation between the expression 
of intracellular glucocorticoid receptors shown as the 
percentage of lymphocytes containing the receptors 
(CD3/GCR) and time interval from the start of steroid 
therapy to complete remission. In a retrospective study, 
Vivarelli et al [13] investigated whether, in children with 
idiopathic NS, the period of time between the onset of 
steroid therapy and complete remission can serve as a 
prognostic indicator, and concluded that the length of 
time between steroid treatment onset and remission is an 
early prognostic indicator for patients with idiopathic NS. 
During follow-up, the median time to achieve remission 
was less than seven days in non-relapsing and infrequent 
relapsing NS  patients, while it was more than seven days 
in frequent relapsing and steroid-dependent NS patients 
[13].
Conclusion
We conclude that evaluation of the expression of 
intracellular glucocorticoid receptors shown as the 
percentage of lymphocytes containing the receptors 
(CD3/GCR) can directly predict early and late responders 
to steroid therapy, and as a result the outcome of nephrotic 
syndrome patients regarding future relapses.
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Figure 4: Scatterplot demonstrating lack of correlation 
between the expression of intracellular glucocorticoid 
receptors by lymphocytes (CD3/GCR) and the urinary 
albumin/creatinine ratio (r=0.01)
Figure 3: Scatterplot demonstrating the negative correlation 
between the expression of intracellular glucocorticoid 
receptors by lymphocytes (CD3/GCR) and the time interval 
from starting steroid therapy to complete remission (r=0.54)
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findings between the two groups. It reported that the 
age of onset in minimal change disease NS was not 
significantly correlated with steroid-responsive rate or 
with the time interval to remission [11]. The number or 
density of cellular GC receptors was found to determine 
cell response and the efficacy of GC on tumour cells in 
lymphoid leukaemia and lymphoma [12]. 
The results of the current study are in accordance with 
a previously cited study which showed that glomerular 
glucocorticoid receptor expression was reduced in late 
responders to steroids in adult-onset minimal change 
disease [10]. Moreover, current results showed a 
significant inverse correlation between the expression 
of intracellular glucocorticoid receptors shown as the 
percentage of lymphocytes containing the receptors 
(CD3/GCR) and time interval from the start of steroid 
therapy to complete remission. In a retrospective study, 
Vivarelli et al [13] investigated whether, in children with 
idiopathic NS, the period of time between the onset of 
steroid therapy and complete remission can serve as a 
prognostic indicator, and concluded that the length of 
time between steroid treatment onset and remission is an 
early prognostic indicator for patients with idiopathic NS. 
During follow-up, the median time to achieve remission 
was less than seven days in non-relapsing and infrequent 
relapsing NS  patients, while it was more than seven days 
in frequent relapsing and steroid-dependent NS patients 
[13].
Conclusion
We conclude that evaluation of the expression of 
intracellular glucocorticoid receptors shown as the 
percentage of lymphocytes containing the receptors 
(CD3/GCR) can directly predict early and late responders 
to steroid therapy, and as a result the outcome of nephrotic 
syndrome patients regarding future relapses.
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Figure 4: Scatterplot demonstrating lack of correlation 
between the expression of intracellular glucocorticoid 
receptors by lymphocytes (CD3/GCR) and the urinary 
albumin/creatinine ratio (r=0.01)
Figure 3: Scatterplot demonstrating the negative correlation 
between the expression of intracellular glucocorticoid 
receptors by lymphocytes (CD3/GCR) and the time interval 
from starting steroid therapy to complete remission (r=0.54)
